News

Market records continue, materials weaker, activity grows in IT sector  The ASX 200 (ASX: XJO) added another 0.2% on Tuesday, with the materials sector the biggest detractor, falling 0.1% under the weight of BHP Group (ASX: BHP) and Rio Tinto (ASX: RIO).  The IT sector continues to surge, adding 1.3%, along with the real estate sector which jumped 1% on somewhat…

Negative start to the week, AUSTRAC on the prowl, takeovers galore The ASX 200 (ASX: XJO) finished down 0.1% on Monday, a negative start to the week driven lower by the financials sector, which fell 1.1%.  Elsewhere the retail sector was hit, falling 0.8% as the Melbourne lockdown continues, whilst the IT sector was the brightest light,…

The Australian market is in a world of its own, pushing ahead with a strong post-pandemic-led recovery while a rebound of the global economy is edging closer, and looks like it will come over the coming quarters. The team at DNR Capital Australian Emerging Companies Fund continues to select quality growth stocks for its Australian…

Thematically focused funds have been the big winners in fund flows in the past three years, but most themes have turned out to be fads, new research shows. According to Morningstar’s latest ‘Global Thematic Funds Landscape Report’, over the three years through March 2021, collective assets under management in the 1,349 thematic funds more than…

ASX finishes at record high, The Reject Shop downgrades, energy leads the week The ASX200 (ASX: XJO) broke 7,300 points for the first time, ultimately finishing up 0.5% on Friday and 1.6% for the week; three consecutive records. On Friday it was 4X4 parts supplier ARB Corporation Limited (ASX: ARB) and Origin Energy (ASX: ORG) leading the way, jumping 6.3% and…

ASX trades off high, retail sales higher, Wesfarmers flags tough comparables   The ASX 200 (ASX: XJO) finished at an all-time high, adding 0.6% on Thursday as the energy sector continued to rally. The energy sector was 3.3% higher along with utilities, up 2% again, whilst consumer discretionary was the only detractor, falling 1.1%. Worley Ltd (ASX: WOR), which…

Australia in rare air, ASX hits another record, Keypath IPO falls flat  The ASX 200 (ASX: XJO) has taken the mantle of overseas markets, hitting another record on Wednesday after moving 1% higher. The energy sector was the biggest contributor with the oil price hitting a two-year high in overnight trading, sending the entire sector up 4%…

The Australian stock market has long been known as the place to be for income-loving investors. Why? Because company dividend yields in Australia are amazingly high. The dividend yield for 2021 and 2022 is forecast to be 4%-5% plus franking, compared to cash rates and fixed-interest products yielding below 1%. According to Morningstar, S&P/ASX 200…

Magellan Financial Group (ASX: MFG) this week released its long-awaited new retirement product called FuturePay. It comes at an important time for the investment and superannuation industry in general, which has seen very little innovation or new product releases focused on delivering more sustainable retirement incomes. So, what is Magellan FuturePay? The product seeks to…

ASX falls but 2% higher in May, Macquarie, Magellan looking to the future The ASX200 (ASX: XJO) fell 0.3% on Tuesday, the first day of winter, with consumer confidence taking a hit as the Victorian lockdown rolls on. Every sector was weaker except energy and materials, which added 1.3% and 0.3% respectively. Healthcare and financials were the…

ASX down on energy, PEXA set to IPO, Nuix downgrades again  The ASX200 (ASX: XJO) started the day strongly, hitting a new record before ultimately closing 0.3% lower as energy, down 1.6%, and the IT sector, -0.9% continued to drag. The weakness comes ahead of a huge week for the Australian economy, with the Reserve Bank of Australia meeting…

Sydney-based drug developer Pharmaxis (ASX:PXS) is moving through a pivot that the market is taking its time to understand, as it takes its lead drug candidate PXS‐5505 firstly through a Phase 1/2a trial for the treatment of the rare bone marrow cancer myelofibrosis, and secondly, into pre-clinical efficacy testing for glioblastoma (GBM), the most common form…